Results 41 to 50 of about 22,335 (252)

Streamlining Diagnosis of Bardet–Biedl Syndrome: New Diagnostic Algorithm With Updated Criteria

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Considerable advances have been made in our understanding of Bardet–Biedl syndrome (BBS), particularly in its core clinical features and molecular genetics, warranting an update to the existing diagnostic criteria framework. Using a rigorous, evidence‐based, and consensus‐driven process, a multidisciplinary group of international experts and ...
Jeremy J. Pomeroy, Jesse Richards, Brooke R. Sweeney, Seema Kumar, Katie E. Queen, Joshua Zaritsky, Carl H. Cramer, Elias I. Traboulsi, Brittni A. Scruggs, Erica E. Davis, Ekaterina Keifer, Emma McGibbon, Timothy Ogden, Bendert De Graaf, Tonia Hymers, Elizabeth Forsythe, Philip Beales   +16 more
wiley   +1 more source

Conjugated bile acid-driven CD14+CD16+ monocyte infiltration promotes cholestatic liver injury by enhancing hepatocyte necroptosis

JHEP Reports
Background & Aims: Cell death and inflammation cause liver injury during cholestasis. Monocyte infiltration is crucial for the inflammatory response in tissues and organs.
Zhixian Zhu, Ziqian Xu, Xinyu Cao, Nan Zhao, Jiaxin Lei, Ling Li, Xi Li, Yan Li, Mingqiao Li, Tian Ren, Li Liu, James L. Boyer, Shi-ying Cai, Qiong Pan, Xiaoxun Zhang, Jin Chai   +15 more
doaj   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

A New Korean Nomenclature for Steatotic Liver Disease

The Korean Journal of Gastroenterology
Background/Aims: Necrotizing pancreatitis (NP) presents a more severe clinical trajectory and increased mortality compared to edematous pancreatitis. Prompt identification of NP is vital for patient prognosis. A risk prediction model for NP among Chinese patients has been developed and validated to aid in early detection.
openaire   +8 more sources

Global trends, epidemiological patterns, and disability burden of metabolic dysfunction-associated steatotic liver disease–related cirrhosis from 1990 to 2021: A comprehensive analysis of the Global Burden of Disease study

Journal of International Medical Research
Objectives To assess long-term global trends in the burden of metabolic dysfunction-associated steatotic liver disease–related cirrhosis and develop a simplified, waist circumference–based prediction model for early identification of individuals at risk ...
Xuli Wang, Bingwei Wang
doaj   +1 more source

Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The recent reclassification of steatotic liver disease into metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated alcohol‐related liver disease has highlighted their potential cardiovascular ...
Minkwan Kim, Minkook Son, Sang Yi Moon, Yang Hyun Baek   +3 more
doaj   +1 more source

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

Chronic Diseases and Translational Medicine, EarlyView.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra   +7 more
wiley   +1 more source

Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer   +4 more
wiley   +1 more source

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Annals of Hepatology
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language.
Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, Quentin M. Anstee, Juan Pablo Arab, Marco Arrese, Ramon Bataller, Ulrich Beuers, Jerome Boursier, Elisabetta Bugianesi, Christopher D. Byrne, Graciela E. Castro Narro, Abhijit Chowdhury, Helena Cortez-Pinto, Donna R. Cryer, Kenneth Cusi, Mohamed El-Kassas, Samuel Klein, Wayne Eskridge, Jiangao Fan, Samer Gawrieh, Cynthia D. Guy, Stephen A. Harrison, Seung Up Kim, Bart G. Koot, Marko Korenjak, Kris V. Kowdley, Florence Lacaille, Rohit Loomba, Robert Mitchell-Thain, Timothy R. Morgan, Elisabeth E. Powell, Michael Roden, Manuel Romero-Gómez, Marcelo Silva, Shivaram Prasad Singh, Silvia C. Sookoian, C. Wendy Spearman, Dina Tiniakos, Luca Valenti, Miriam B. Vos, Vincent Wai-Sun Wong, Stavra Xanthakos, Yusuf Yilmaz, Zobair Younossi, Ansley Hobbs, Marcela Villota-Rivas, Philip N. Newsome   +52 more
doaj   +1 more source

Hepatic Mechanisms and Therapeutic Target Underpinning Hypercoagulation in Obesity: Insights From Genetic and Transcriptomic Analyses

Exploration, EarlyView.
Obesity‐linked hypercoagulation is driven by fibrinogen overproduction in a specific hepatocyte cluster via IL6 signalling. Genetic and mechanistic studies reveal this pathway as a key target for therapies to mitigate clotting risks and associated complications in obese individuals.
Shumin Li, Gengchen Feng, Xin Huang, Xiao Teng, Ziyi Yang, Yue Liu, Yonghui Jiang, Tao Zhu, Teng Liu, Yunfei Xu, Chang Pan, Han Zhao, Shaozhuang Liu, Shigang Zhao, Zi‐Jiang Chen   +14 more
wiley   +1 more source